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differentiate bladder cancer from hernia. SAA4 was significantly increased in bladder
cancer subgroups, whereas ProEGF was significantly decreased in bladder cancer sub-
groups. Additionally, the combination of SAA4 and ProEGF exhibited higher diagnostic
capacity (AUC = 0.80 and p < 0.001) in discriminating bladder cancer from hernia than
either marker alone. Using MetaCore software to interpret global changes of the urine
proteome caused by bladder cancer, we found that the most notable alterations were in
immune-response/alternative complement and blood-coagulation pathways. This study
confirmed the clinical significance of the urine proteome in the development of
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In this study, we evaluated the reproducibility of abundant urine protein depletion by
hexapeptide-based library beads and an antibody-based affinity column using the iTRAQ
technique. The antibody-based affinity-depletion approach, which proved superior, was then
applied in conjunction with iTRAQ to discover proteins that were differentially expressed
between pooled urine samples from hernia and bladder cancer patients. Several proteins,
including seven apolipoproteins, TIM, SAA4, and proEGF were further verified in 111 to 203
individual urine samples from patients with hernia, bladder cancer, or kidney cancer. SAA4
was significantly increased in bladder cancer subgroups, whereas ProEGF was significantly
decreased in bladder cancer subgroups. Additionally, the combination of SAA4 and ProEGF
exhibited higher diagnostic capacity in discriminating bladder cancer from hernia than either
marker alone. A marker panel composed by two novel biomarker candidates, SAA4 and
proEGF, was first discovered and verified successfully using Western blotting. To the best of
our knowledge, the associations of urinary SAA4 and proEGF with bladder tumor and kidney
cancer havenot beenmentioned before. In the present study,wediscovered and verified SAA4
and proEGF as potential bladder cancer biomarker for the first time.
© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
Bladder cancer is one of the most common urinary tract
carcinomas. According to the most recent estimates of the
AmericanCancer Society, therewere 69,250 newcases of bladder
cancer in the United States and 14,990 deaths from bladder
cancer annually in 2011 [1]. Major risk factors for the develop-
ment of bladder cancer include cigarette smoking and exposure
to specific carcinogens [2].
Prominent among the major clinical problems associated
with bladder cancer is the high recurrence rate of superficial
tumors; 50–70% of newly diagnosed tumors recur within five
years and progression to invasive disease will occur in 10–20%
of patients. Therefore, patients with bladder tumors must
undergo life-long surveillance [3]. This requirement for lifetime
surveillance, taken together with the cost to treat recurrent
bladder cancer tumors and complications associated with
treatment, imposes a significant economic burden. Screening
of high-risk populations may be beneficial in the detection of
early-stage tumors before they become invasive or in surveil-
lance to detect recurrence [4]. Thus, themost important clinical
challenges are early detection of bladder tumors and discovery
of non-invasive stage/grade discriminators or predictors of
tumor progression. Integration of multiple markers has the
potential to further improve bladder cancer diagnosis and
progression monitoring.
Urine, derived from plasma by filtration through the renal
glomerulus, has become one of the most widely used clinical
samples for biomarker discovery. It is estimated that approxi-
mately 70% of urinary proteins are derived from the kidney and
urinary tract [5–7]. Many abundant plasma proteins are also
present at high concentrations in urine specimens [8–10],
making it more difficult to detect potential biomarkers present
at low concentrations. Antibody-based affinity-depletion ap-
proaches are able to simultaneously remove several of themost
abundant proteins from various kinds of body fluids in a single
step [11–13]. Simply removing 2 to 20 of the most abundant
proteins using immune-depletion approaches has been shown
to allowmoreprotein spots to be visualized by two-dimensional
electrophoresis or a larger number of proteins to be identifiedusing liquid chromatography (LC)-based proteomic strategies
[14,15].
An alternative strategy for enriching low-abundance proteins
uses a combinatorial hexapeptide ligand library immobilized on
a solid-phasematrix [16–18]. The amount of each specific protein
captured by the library is limited by the number of the ligands
with suitable affinity interaction. Saturation of affinity ligands
limits the amounts of abundant proteins captured, preventing
retention of an excess of highly abundant proteins. Therefore,
the concentrations of low-abundant proteins are enriched
relative to the original composition of the specimen, decreasing
the dynamic range of the concentration difference in a biological
sample. However, the interaction of a complicated peptide
mixture with a random peptide library is an intricate process
that can be affected by competition amongmultiple association/
dissociation mechanisms, kinetics of binding affinity, and
stoichiometry. When this approach is applied to the discovery
of biomarkers in biological fluids, poor reproducibility of the
depletion step may cause problems in candidate selection in
subsequent proteomic studies. Although hexapeptide-based
library beads and columns containing immobilized antibodies
arewidely used techniques for depletion of abundant proteins in
body fluids [16,17], detailed characterizations and comparisons
of the two approaches have been limited [17,19], particularly for
specimens of urine, a biofluid with low protein levels but a high
salt concentration.
In this study, we used the iTRAQ (isobaric tags for relative
and absolute quantitation) technique to evaluate the reproduc-
ibility of abundant-protein depletion using hexapeptide-based
library beads and an antibody-based affinity column—the
Agilent human 14 multiple affinity removal system (MARS)
column. The antibody-based affinity-depletion approach was
then applied in conjunction with iTRAQ to discover proteins
differentially expressed between pooled urine samples from
age-matched hernia and three subgroups of bladder cancer
patients. Several proteins present at markedly different levels
were further verified in individual samples using Western blot
analyses and a multiplexed Bio-plex assay. The verified pro-
teinswere found to be potentialmarkers for early detection and
diagnosis of bladder cancer.
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2.1. Clinical specimens
Clinical specimens were collected using a previously described
protocol [20]. Briefly, firstmorning urine sampleswere collected
in the presence of a protease inhibitor cocktail tablet (one tablet
per 50 mL urine; Roche, Mannheim, Germany) and sodium
azide (1 mM) from hernia volunteers and bladder cancer
patients. Hernia patients were served as controls from cancer
patients with comparable age and exactly the same procedures
of urine sample collection in the first morning after admission
before surgical intervention. The collected urine samples were
centrifuged at 5000 ×g for 30 min at 4 °Cwithin 5 h of collection
to remove cells and debris, and the clarified supernatants were
stored at −80 °C for further processing. All urine samples were
collected at Chang Gung Memorial Hospital, Taoyuan, Taiwan.
The study protocol was approved by the Medical Ethics and
Human Clinical Trial Committee at Chang Gung Memorial
Hospital. The bladder cancer patients recruited in this study
were a mixed population containing non-muscle invasive and
muscle invasive patients, however, have categorized clearly
into three subgroups according to the TNM (tumor, node,
metastasis) staging system [21,22]. The three subgroups were
low grade with early stage (LgEs), high grade with early stage
(HgEs), and high grade with advanced stage (HgAs). LgEs and
HgEs BC patients were non-muscle invasive bladder cancer
subgroups. HgAs BC patients were muscle-invasive subgroup.
2.2. Concentration and desalting of urine samples
Urine proteins were enriched using a 10-kDa centrifugal filter as
described by the manufacturer (Millipore, Carrigtwohill, Ireland).
Briefly, 12.5-mL urine samples were centrifuged at 5000 ×g for
30 min at 4 °C in the filter tube, and then the tube was refilled
with 12.5 mL of 20% acetonitrile/H2O and centrifuged again. This
process was repeated once using pure water for desalting
purposes. For iTRAQ labeling, samples were subjected to an
additional desalting step using 4 mL H2O to prevent against
possible interference bymetabolites in the labeling reaction. The
amount of protein in each concentrated/desalted urine sample
wasmeasured using aDCprotein assay kit (Bio-Rad Laboratories,
Hercules, CA, USA), then the sample was lyophilized and stored
at −80 °C for subsequent processing.
2.3. Depletion of abundant proteins using MARS column
Urine protein for the discovery phase was obtained from
individual urine samples subjected to depletion of 14 abundant
proteins using an Agilent Human 14 MARS Column (Agilent,
Palo Alto, CA, USA), which contains antibodies raised against
human epitopes of albumin, IgG, antitrypsin, IgA, transferrin,
haptoglobin, fibrinogen, α2-macroglobulin, α1-acid glycoprotein,
IgM, apolipoprotein Al, apolipoprotein All, complement C3, and
transthyretin. Urine protein (1 mg) from each individual was
processed according to the manufacturer's protocol (Agilent).
Briefly, desalted/concentrated urine protein was prepared at
1 mg/40 μL in H2O, and then diluted to 1 mg/160 μL by the
addition of 120 μL buffer A of the MARS column system.The diluted urine protein was then processed using the
recommended column run cycle consisting of sample loading,
flow-through collection (depleted fraction), washing, and elution
of bound proteins by buffer B of the MARS column system. The
column was then re-equilibrated for the next depletion run.
Depleted and retained urine proteins were concentrated using
3000-MW cut-off concentrators (Millipore, Ireland), quantified
using a DC protein assay kit (Bio-Rad Laboratories) and then
stored at −20 °C for further use. Abundant-protein-depletion
reproducibility and effect on protein identification were
evaluated using pooled urine proteins from 12 normal
individuals (six males and six females) as a model sample. The
model sample was assessed by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE), and LC-tandem
mass spectrometry (MS/MS) analyses of 20 fractions generated
using basic reverse-phase chromatography.
2.4. Depletion of abundant proteins using ProSpectrum
Library hexapeptide beads
ProSpectrum Library PSL-2 resin (4 mg; Proloas, Florence, KY,
USA) was loaded onto a spin column (Micro Bio-Spin
chromatography columns; BioRad Laboratories) and activated
in swelling reagent (50% methanol) for 10 min. After removal
of the supernatant, the resin was washed twice with 500 μL of
H2O and then suspended in 500 μL of H2O. Model sample urine
protein (10 mg) was incubated with resin at room temperature
for 1 h. After incubation, samples were spun to pellet resin
beads. The flow-through fraction containing high-abundance
proteins was collected and stored at −20 °C until subsequent
SDS-PAGE characterization. Resin beads were washed three
times with H2O. Finally, resin beads were incubated with
500 μL of 9 M urea containing 2% CHAPS for 1 h at room
temperature and then spun to elute bound proteins (eluate
fraction). The eluate fraction buffer was then changed to
water using a centrifugal filter device (Amicon Ultra-4
Centrifugal Filter Device-3000NMWL; Millipore, Cork, Ireland)
and stored at −20 °C until subsequent SDS-PAGE characteri-
zation and iTRAQ-labeling.
2.5. iTRAQ labeling
The technical performance of the two depletion methods—
MARS column and ProSpectrum Library—was evaluated by
individually processing themodel sample in triplicate using the
two depletion methods. An internal standard sample was
prepared by mixing equal amounts of the MARS- and
ProSpectrum Library-depleted samples. The process-triplicate
samples were labeled with iTRAQ reagents using tags 115–117
andmixedwith the internal standard (tag 114) for two rounds of
iTRAQ experiments, as described in Supplemental Fig. 1. The
intensity of the reporter ionwas then used to calculate the ratio
of the corresponding peptides.
In the biomarker discovery-phase experiment, age-matched
hernia patients were chosen as the control subgroup. All hernia
and bladder cancer patients were older than 45 years of age.
Detailed information about these samples is presented in
Supplemental Table 1. The four subgroups in four-plex iTRAQ
were classified as hernia and three bladder cancer subtypes,
LgEs, HgEs, and HgAs. After abundant-protein depletion, equal
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histological grades or pathological stages were pooled into a
subgroup to minimize individual variation (hernia, n = 7; LgEs,
n = 4; HgEs, n = 5; HgAs, n = 4) in the discovery-phase experi-
ment. Pooled urine protein (100 μg) from each subgroup was
processed according to the manufacturer's protocol for the
four-plex iTRAQ (Applied Biosystems, Foster City, CA, USA).
Briefly, one unit of iTRAQ reagent (defined as the amount of
reagent required to label 100 μg of protein) was thawed and
reconstituted in 70 μL of ethanol. Pooled urine protein in each
subgroup was reduced, cysteine-blocked, and digested with
trypsin. Tryptic peptides of hernia, LgEs, HgEs, and HgAs
bladder cancer subgroups were labeled with iTRAQ tags 114,
115, 116 and 117, respectively, by incubation at room temper-
ature for 1 h. The peptide mixtures were then pooled and dried
by vacuum centrifugation.
2.6. Fractionation by basic reverse-phase chromatography
For reverse-phase chromatography under basic conditions,
tryptic peptides and iTRAQ-labeled peptideswere reconstituted
in 0.5 mL of buffer C (ammonium hydroxide aqueous solution,
pH 10) and loaded onto a 4.6 mm × 150 mm Gemini C18
column containing 3-μm particles with a 160-μm pore size
(HPLC Phenomenex, Torrance, CA, USA). The peptides were
eluted at a flow rate of 400 μL/min with the following gradient:
2% buffer D (ammonium hydroxide in 100% acetonitrile, pH 10)
for 5 min, 2–35% buffer D for 40 min, 35–60% buffer D for 5 min,
60–95% buffer D for 3 min, and 95% buffer D for 3 min. The
column was then equilibrated in 2% buffer D prior to the next
injection. The elution wasmonitored bymeasuring absorbance
at 220 nm, and fractionswere collected every 1 min. The eluted
fractions were readied for nano ESI-LC–MS/MS analysis by
pooling into 42 fractions and vacuum drying.
2.7. LC-ESI MS/MS analysis by LTQ-Orbitrap
Each peptide fraction was reconstituted in buffer E (0.1% formic
acid in H2O). Peptides (2 μg) from each fraction were loaded onto
a trap column (Zorbax 300SB-C18, 0.3 × 5 mm; Agilent Technol-
ogies, Wilmington, DE, USA) at a flow rate of 20 μL/min in buffer
E, and separated on a resolving 10-cm analytical BioBasic C18
PicoFrit column (inner diameter, 75 μm) with a 15-μm tip (New
Objective,Woburn, MA, USA). Peptides were eluted at a flow rate
of 0.25 μL/min across the analytical columnwith linear gradients
of 5%–30% buffer F (0.1% formic acid in 99.9% acetonitrile) for
40 min, 30%–45% buffer F for 5 min, and 45%–95% buffer F for
2 min, followed by maintenance in 95% buffer F for 4 min.
The LC setup was coupled in-line to a linear ion trap
(LTQ)-Orbitrap (Thermo Fisher, San Jose, CA, USA) operated
using XCalibur 2.0 software (Thermo Fisher). Intact peptides
were detected in the Orbitrap at a resolution of 30,000. Internal
calibrationwas performed using the ion signal of (Si(CH3)2O)6H+
at m/z 445.120025 as a lock mass [23]. In the analysis of
iTRAQ-labeled peptides, peptides selected for MS/MS were
fragmented using pulsed-Q dissociation (PQD) and the resulting
ion fragments were detected in the LTQ. A data-dependent
procedure that alternated between one MS scan followed by
three MS/MS scans was applied for the three most abundant
precursor ions in the MS survey scan. The m/z values selectedfor MS/MS were dynamically excluded for 180 s. The
electrospray voltage applied was 1.8 kV. Both MS and MS/MS
spectrawere acquired using the 4microscanwithmaximum fill
times of 1000 and 100 ms for MS and MS/MS analysis,
respectively. Automatic gain control was used to prevent
over-filling of the ion trap; 5 × 104 ions were accumulated in
the ion trap for generation of PQD spectra. ForMS scans, them/z
scan range was 350 to 2000 Da.
2.8. Protein identification and quantitation by sequence
database searching
The resulting MS/MS spectra were searched against the
European Bioinformatics Institute (http://www.ebi.ac.uk/)
non-redundant International Protein Index human sequence
database (v3.55 February 2009) containing 75,554 sequences
using the MASCOT engine (version 2.2.04; Matrix Science,
London, UK) with the Mascot Daemon program (version 2.2.0;
Matrix Science). For protein identification, a mass tolerance of
10 ppm was permitted for intact peptide masses and 0.5 Da for
PQD-fragmented ions, with allowance for twomissed cleavages
in the trypsin digests and oxidized methionine as a potential
variable modification. iTRAQ (N terminal), iTRAQ (K), and
methyl methanethiosulfonate (C) were set as fixed modifica-
tions for iTRAQ-labeled samples. The charge states of peptides
were set to +2 and +3.
Protein identification for evaluation of depletion approaches
by LC-PQD-MS/MS was summarized using Scaffold (version
2_02_01; Proteome Software, Proteome Software Inc., Portland,
OR, USA). Identification and quantification of proteins in iTRAQ
experiments were validated using the open source Trans-
Proteomic Pipeline (TPP) software (Version 4.0). The MASCOT
search resulted in a DAT file for each fraction. The MS raw data
and DAT files containing peak list information for identified
peptides were then processed and analyzed using the TPP
software. The TPP software includes PeptideProphet, a peptide
probability score program that aids in the assignment of peptide
MS spectra [24], and ProteinProphet, a program that assigns and
groups peptides to a unique protein or a protein family if the
peptide is shared among several isoforms [25]. ProteinProphet
allows filtering of large-scale data sets with assessment of
prediction sensitivity and false-positive identification error
rates. In this study, we used PeptideProphet and ProteinProphet
probability scores ≥0.95 to ensure an overall false-positive rate
less than 0.53%. The ratio of each protein was quantified using
the Libra program, a module within the TPP software package
that performs quantification on MS/MS spectra that have
multiplexed labeled peptides. The minimum intensity threshold
of a reporter ion was 20 in the spectrum of a Libra peptide. The
default parameters of the Libra programwere used to remove the
outlier ratios of peptide quantitation. Each quantified protein
contained at least one Libra peptide. Information about the
PeptideProphet, ProteinProphet, and Libra programs in the TPP
software can be obtained from the Seattle ProteomeCenter at the
Institute for Systems Biology (http://www.proteomecenter.org/).
2.9. Western blot analysis
Urine protein (100 μg) from individual or pooled samples was
resolved on an SDS gel and transferred electrophoretically to a
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tories). The membrane was blocked with 5% non-fat dried
milk in TBST (Tris-buffered saline [Bio-Rad Laboratories]
containing 0.1% Tween-20 [Sigma, St. Louis, MO, USA]) for
1 h at room temperature. The following antibodies were
used for Western blot analysis: anti-apolipoprotein A4
(anti-APOA4, 1:10,000, LS-B2417; Lifespan Biosciences, Seattle,
WA, USA), anti-vitamin D-binding protein (anti-VDBP, 1:2000,
sc-32899; Santa Cruz Biotechnology, Santa Cruz, CA, USA),
anti-triosephosphate isomerase (anti-TIM, 1:1000, sc-30145;
Santa Cruz Biotechnology), anti-serum amyloid A-4 protein
precursor (anti-SAA4, 1:1000, H00006291-D01P; Abnova), and
anti-EGF (anti-epidermal growth factor, 1:2000, sc-275; Santa
Cruz Biotechnology). The membranes were probed by incu-
bating first with primary antibody and then with horseradish
peroxidase-conjugated secondary antibody, and developed
using enhanced chemiluminescence detection according to
the manufacturer's instructions (PerkinElmer, Netherlands or
Millipore, MA, USA). An internal standard from a pooled urine
sample was included in each Western blot analysis and used
to normalize the intensity of each target protein detected.
2.10. Immunobead-based suspension array system for
detection of urine apolipoproteins
The urine levels of six apolipoproteins (APO A1, A2, B, C2, C3,
and E) were determined with the MILLIPLEX MAP Human
Apolipoprotein Panel kit (Millipore, MA, USA) using the
Bio-Plex system (Bio-Rad Laboratories). The assay procedure
was a modification of the blood sample-suitable protocol
provided byMillipore. Briefly, filter-bottom, 96-wellmicroplates
were pre-wetted with wash buffer (Millipore) and blocked for
10 min with assay buffer (Millipore). A standard curve was
generated by preparing 5-fold serial dilutions of appropriate
standards inassay buffer. Tenmicroliters of prepared standards
and urine samples (2-fold dilution) were added into wells
containing 90 μL of assay buffer with immunobead mixtures.
Microplates were then incubated for 50 min at room tempera-
ture on a microtiter shaker in the dark and then washed three
times with wash buffer using a vacuum manifold (Millipore).
The mixture of biotin-conjugated detection antibodies was
added to the wells and plates were incubated for 30 min. After
washing, phycoerythrin–streptavidin was added and plates
were incubated for 30 min. Finally, the washed immunobeads
were resuspended in sheath buffer (Bio-Rad Laboratories) and
analyzed using the Bio-Plex 200 system (Bio-Rad Laboratories).
Standard curves and analyte concentrations were obtained
using Bio-Plex Manager software version 4.2 (Bio-Rad
Laboratories).
2.11. Statistical analysis
The statistical package SPSS 13.0 (SPSS Inc., Chicago, IL, USA)
was used for allWestern blotting andBio-plex systems analyses
of protein expression levels in individual samples. Differences
in concentration levels of targeted urine proteins in relation to
different clinical parameters were analyzed using the nonpara-
metric Mann–Whitney U test. Receiver operator characteristic
(ROC) curve analysis and area under the curve (AUC) analysis
were applied to detect the optimal cutoff point that yielded thehighest total accuracy with respect to discriminating different
clinical classifications. A p-value less than 0.05 was considered
statistically significant.
2.12. Network analysis
A network analysis of differentially expressed proteins identi-
fied in each clinical set was performed using the MetaCore
analytical suite version 5.3 (GeneGo, Inc., St. Joseph, MI, USA).
Hypothetical networks of proteins from our experiments and
proteins from the MetaCore database were built using the
algorithms integrated within MetaCore. The statistical signifi-
cance of the identified networks was based on p-values, which
are defined as the probability that a given number of proteins
from the input list willmatch a certain number of gene nodes in
the network. The relevant pathway maps were then prioritized
based on their statistical significance (p < 0.001).3. Results
3.1. Improvement of protein identification using two
abundant-protein-depletion approaches
In order to more easily isolate and identify minor proteins in
urine, we used the MARS column to chromatographically
remove 14 high-abundance proteins from two pooled urine
samples. Removal of these abundant proteins is expected to
improve the subsequent LC/MS and electrophoretic analysis of
the urine sample by effectively expanding the dynamic range of
the detection. A second approach, ProSpectrum peptide library,
was also used to process urine proteins to compress the protein
concentration range. Twopooled clinical urine protein samples,
one from nine bladder cancer patients and the other from nine
hernia controls, were used to assess the improvement in
protein identification after processing samples individually
with the two depletion approaches. Each sample was fraction-
ated into 20 fractions using basic reverse-phase chromatogra-
phy and analyzed using nano LC–MS/MS. The results of this
analysis are summarized in Table 1, which shows the numbers
of identified peptides and proteins with false-positive rates less
than 0.5%. Prior to depletion, a total of 323 proteins (1390 unique
peptides) were identified in the pooled hernia patient urine
sample, and 309 proteins (1548 unique peptides) were identified
in the urine sample from bladder cancer patients. Following
depletion of high-abundance proteins using the MARS Hu-14
depletion column, 512 proteins (2698 unique peptides) were
identified in the hernia patient sample and 479 proteins (2377
unique peptides) were identified in the bladder cancer sample.
After depletion using ProSpectrum Library beads, 495 proteins
(2525 unique peptides) were identified in the hernia sample and
551 proteins (3480 unique peptides) were identified in the
bladder cancer sample. These results indicate that both the
MARS Hu-14 depletion column and ProSpectrum Library beads
resulted in an increase in the number of identified proteins
(1.53- to 1.78-fold) and peptides (1.54- to 2.25-fold) in the urine
proteome, an improvement in the detection of minor proteins
that is expected to improve biomarker discovery in the urine
proteome.
Table 1 – Protein identification of hernia and bladder cancer urine proteome before and after abundant protein depletion by
MARS column and ProSpectrum Libraries™ Hexapeptide Beads.
Description Without depletion MARS Hu-14 depletion a Prospectrum libraries
depletion b
Hernia Bladder cancer Hernia Bladder cancer Hernia Bladder cancer
Identified proteins 323 309 512 479 495 551
Identified peptides 1390 1548 2698 2377 2525 3480
a The total amount of input protein was 1 mg.
b The total amount of input protein was 10 mg.
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protein-depletion approaches using the iTRAQ platform
Fig. 1 shows representative results of an SDS-PAGE analysis of
urine protein patterns from a pooled normal urine specimen
from 12 healthy volunteers (six males and six females) before
and after preparation by ProSpectrum Library beads and the
MARS Hu-14 depletion column. The SDS-PAGE analysis revealed
a dramatic change in the protein profiles of urine samples after
depletion. The average recovery rates were 26.5% ± 1.9% and
1.5% ± 0.1% for the MARS column (1 mg starting urine protein)
and ProSpectrum Library beads (10 mg starting urine protein),
respectively. As shown in Fig. 1, the MARS column removed
the specific target proteins of the antibodies; however, many
non-target proteins were also removed from the original
samples. Depleted fractions from samples processed using
ProSpectrum Library beads tended to be enriched for
low-molecular-weight proteins (<21 kDa). This observation is
consistent with the findings of Bandhakavi et al., who reported
that the use of hexapeptide beads enriched proteins with small
to medium molecular weights in the saliva proteome [16]. This
phenomenon is important for urine proteome analysis becauseFig. 1 – Protein profiles of a pooled model sample obtained by pro
compared using SDS-PAGE. Equal amounts of protein (4 μg/lane
(triplicates), fractions of high-abundance proteins generated usin
of depleted proteins generated using ProSpectrum Library beads
reference molecular weight markers; lanes 10–12 (triplicates), fra
column; lanes 13–15 (triplicates), fractions of high-abundance prmajor urine proteins are relatively smaller owing to the filtration
function of kidney. Low-abundance proteins with lowmolecular
weightmay thus becomemore easily detectable after processing
with hexapeptide beads.
The pooled normal urine sample was then used to evaluate
the two approaches in terms of reproducibility of sample
preparation. A mixture of depleted protein samples prepared
by the two approaches was labeled with the iTRAQ 114 tag and
used as an internal standard. Equal amounts of depleted
protein samples, labeled with 115, 116 and 117 tags in two
iTRAQ experiments, were processed independently in triplicate
according to the experimental design shown in Supplemental
Fig. 1. A total of 246 proteins were quantified between the two
iTRAQ experiments. A detailed list of proteins and peptides
obtained through iTRAQ analysis is presented in Supplemental
Table 2. To assess the experimental variation that occurred at
the depletion step, we calculated the coefficient of variation
(CV) of the 246 quantified proteins using 115/114, 116/114, and
117/114 ratios.We further classified the quantified proteins into
subgroups according to thenumber of Libra peptides, defined as
peptides used to quantify a specific protein, and calculated the
average CV values of the subgroups. Average CV values plottedcessing with ProSpectrum Library beads and a MARS column
) were separated on 12.5% gels and silver stained. Lanes 1–3
g ProSpectrum Library beads; lanes 4–6 (triplicates), fractions
; lane 7, original protein without depletion. Lanes 8 & 9,
ctions of depleted proteins generated using a MARS Hu-14
oteins generated using a MARS Hu-14 column.
Table 2 – Protein identification and quantification results







(I) BCa>hernia b All Ratios c ≥ 1, and Any Ratio d ≥ 2 152
(II) Hernia>BC All Ratios ≤ 1, and Any Ratio ≤ 0.5 130
(III) No significant
change
0.5 < All Ratios < 2 225
(IV) Others (QP)–(I)–(II)–(III) 79
a BC: Bladder cancer.
b Hernia: Non-tumor control.
c All Ratios: 115/114, 116/114 and 117/114 ratios.
d Any Ratio: 115/114, 116/114 or 117/114 ratio.
34 J O U R N A L O F P R O T E O M I C S 8 5 ( 2 0 1 3 ) 2 8 – 4 3against the Libra peptide number of a protein is shown in Fig. 2,
which indicates that themore Libra peptides used to quantify a
protein, the smaller the CV value. A smaller CV should facilitate
the selection of biomarker candidates for further verification.
The regression analysis shown in Fig. 2 indicates that the
average CV values of the two depletion approaches were each
less than 25% (Libra peptide number ≥1). When a protein was
quantified with one Libra peptide, CV values were ~15% and
20% for MARS and ProSpectrum Library beads, respectively.
When four Libra peptidesper proteinwere used, CV valueswere
kept close to 10% for MARS column-depleted samples but were
slightly greater than 15% for samples depleted by Spectrum
Library beads. CV values less than 10% in ProSpectrum Library
bead-depleted samples were only observed for proteins quan-
tified using more than ten Libra peptides, which may only be
attainable for medium- to high-abundance proteins. The MARS
column thus appears to bemore quantitatively reproducible for
the depletion of abundant urine proteins under our experiment
conditions. Therefore, to discover candidate biomarkers for
bladder cancer, we used the MARS column in conjunction with
iTRAQ-labeling and LC–MS/MS in subsequent comparative
urine proteomic studies.
3.3. Comparative analysis of the depleted urine proteome
in the discovery of bladder cancer biomarkers
For the discovery phase of this study, equal amounts of
abundant-protein-depleted urine protein samples from
individuals were pooled into subgroups. The four subgroups
in four-plex iTRAQ were classified as hernia and bladder
cancer subtypes LgEs, HgEs, and HgAs, determined according
to the TNM staging system [21,22]. A total of 644 urine proteins
were identified in the iTRAQ experiment, of which 586 had at
least one Libra peptide (Supplemental Table 3). iTRAQ ratios of
this latter group were quantified, and those displaying a
fold-difference ≥2 or ≤0.5 between any tumor subgroup and
the hernia subgroup were defined as increased or decreased
proteins, respectively, as described in our previous study [20].












NO. of Libra peptide
MARS Hu-14
Prospectrum Libraries
Fig. 2 – Reproducibility of the abundant-protein-depleted
urine proteome using each of the two depletion approaches.
Reproducibility was evaluated by plotting average CV values
versus Libra peptide number of an identified protein.four categories: (I) bladder cancer > hernia: 152 proteins; (II)
bladder cancer ≤ hernia: 130 proteins; (III) non-significant
difference: 225 proteins; and (IV) others: 79 proteins. The
numbers of quantified proteins in each subgroup are sum-
marized in Table 2.
3.4. Validation of iTRAQ quantitative results in pooled
urine samples by Western blot analyses
To avoid possible interference due to co-elution of isobaric
peptides and to confirm the iTRAQ results, we selected three
proteins, TIM, VDBP and proEFG, for quantification by
Western blot analyses of the pooled samples originally used
for the iTRAQ experiment. iTRAQ ratios and Western blot
analyses showed similar quantitative trends in proteins
between bladder cancer and control subgroups (Fig. 3); the
levels of TIM and VDBP were increased and proEGF was
decreased in all subgroups of bladder cancer specimens. The
Western blotting results confirmed the reliability of MS-based
quantitation for the urine proteome.
3.5. Biomarker verification of apolipoproteins using a
Bioplex assay
In the iTRAQ dataset, apolipoproteins APOA1, APOA2, APOA4,
APOB, APOE, and APOM were present at elevated levels in
bladder cancer urine specimens. Therefore, we first sought to
verify the elevated levels of multiple apolipoproteins in 111
individual urine samples (48 hernia, 20 LgEs, 33 HgEs, and 10
HgAs) using the Human Apolipoprotein Kit, which is
commercially available as a 96-well plate immunoassay for
multiplexed detection of APOA1, APOA2, APOB, APOC2,
APOC3, and APOE. As shown in Fig. 4A–F, Supplemental
Table 4 and summarized in Table 3, this assay revealed that
these six urine apolipoproteins were significantly higher in BC
subgroups compared to hernia (n = 111), validating the results
of the iTRAQ analysis. The levels of all six proteins were
significantly different between bladder cancer and hernia
(p < 0.001 and AUC > 0.7); thus, each protein was able to
differentiate these conditions. APOA1 had the largest AUC
value (0.875). This result re-confirms our previous work on
the quantitation of urinary APOA1 in individual hernia and
Fig. 3 – Verification of the three selected proteins, VDBP, TIM and proEGF, in pooled urine samples by Western blot analyses.
Proteins (50 μg) from pooled urine samples used for the original iTRAQ experiment were subjected to Western blot analysis
(WB). Fold-differences of target protein levels in cancer subgroups relative to the hernia group are denoted below each blot
(right panel). LC–MS/MS quantification results (in the low mass reporter ion region) and identification of the three selected
candidate biomarkers are shown in the left panel.
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assays [10,20]. AUC values of the remaining five proteins
ranged from 0.739 to 0.864. Five of the six validated proteins
(APOA1, APOA2, APOB, APOC2 and APOC3) also showed
significant differences between hernia and low grade/early
stage bladder cancer, with AUC values ranging from 0.713 to
0.791. These findings indicate that the six apolipoproteins are
potential urine biomarkers for the diagnosis of bladder cancer.
With the exception of APOE, they may also be useful in the
early detection of bladder tumors.
3.6. Verification of potential biomarkers APOA4, TIM,
SAA4 and ProEGF by Western blot analysis in 163 to 174
individual urine samples
On the basis of the iTRAQ results and potential relevance in
human cancer, we selected four additional candidates,
APOA4, TIM, SAA4 and ProEGF, for verification in individual
samples by Western blotting. According to the iTRAQ results,
urinary concentrations of APOA4, TIM, and SAA4 were
elevated and those of ProEGF were decreased in all subgroups
of pooled bladder cancer. We then analyzed the levels of the
four proteins in 163 to 174 individual urine samples by
Western blotting; the results are shown in Figs. 5A and 6A,Supplemental Figs. 2A and 3A, and, Supplemental Table 4.
The LgEs/hernia, HgEs/hernia, and HgAs/hernia ratios for
APOA4were 1.0, 5.6, 4.4, and 5.8, respectively, in the individual
samples (Supplemental Fig. 2B). For TIM, the ratios for LgEs/
hernia, HgEs/hernia, and HgAs/hernia were 0.9, 1.1, and 1.6,
respectively (Supplemental Fig. 3B). However, a statistical
analysis indicated that neither APOA4 nor TIM levels were
significantly increased in bladder cancer (Table 4), indicating
that TIM and APOA4 are probably not useful urine biomarkers
for bladder cancer diagnosis.
A Western blot analysis of the remaining two candidate
proteins, SAA4 and ProEGF, using 174 individual samples
showed a similar trend to the iTRAQ results. SAA4 levels were
increased 4.0- to 17.0-fold in bladder cancer compared to
hernia subgroups (n = 174; Fig. 5B), and ProEGF was decreased
by 70–90% in bladder cancer compared to hernia subgroups
(n = 163; Fig. 6B). Both SAA4 and ProEGF levels were signifi-
cantly altered in all bladder cancer specimens (p ≤ 0.05),
indicating SAA4 and ProEGF are potentially useful biomarkers
for detecting bladder cancer. Table 4 summarizes the diag-
nostic efficacies of urine SAA4 and ProEGF in bladder cancer
detection or as stage/grade discriminators. The AUC values
derived from ROC curve analyses were 0.68 and 0.71 for SAA4
and ProEGF, respectively, for discriminating bladder cancer
Fig. 4 – Validation of six apolipoproteins using a multiplexed Bio-plex assay. Concentrations of six urine apolipoproteins were
elevated in BC subgroups compared to hernia (n = 111). All six proteins were able to differentiate bladder cancer from hernia
with statistical significance.
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a higher concentration of urinary SAA4 than patients with
low-grade bladder cancer (AUC = 0.75 and p < 0.001; n = 99).
The decreased level of ProEGF was also significantly differ-
ent between hernia and the LgEs bladder cancer subgroup
(n = 88), suggesting promise in the early detection of cancer
(Table 4).It is thought that biomarker panels consisting of multiple
biomarkers can provide greater specificity and sensitivity than
each biomarker alone, as each of the single biomarker
contributes independent diagnostic information [26]. The use
of a biomarker panel usually relies on an interpretation of the
pattern of the different biomarkers in relation to one another
rather than the absolute levels of each biomarker. Accordingly,
Table 3 – Summary of the p values, AUC values of the ROC
curves, sensitivity and specificity of the six apolipoproteins
assessed by Bioplex in constant volume of individual urine
samples.
Protein Hernia vs.
LgEs (n = 68)
Hernia vs. all
BC (n = 111)
Lg BC vs. Hg BC
(n = 63)
p value AUC p value AUC p value AUC
ApoA1 <0.001 0.777 <0.001 0.875 0.053 0.652
ApoA2 <0.001 0.791 <0.001 0.864 0.084 0.636
ApoB <0.001 0.719 <0.001 0.739 0.837 0.516
ApoC2 <0.001 0.738 <0.001 0.838 0.025 0.676
ApoC3 <0.001 0.713 <0.001 0.835 0.024 0.677
ApoE 0.11 0.623 <0.001 0.745 0.046 0.657
Statistically significant values (p value ≤0.050 or AUC values >0.7)
are highlighted in bold.
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discovered biomarkers, SAA4 and ProEGF. The combination of
SAA4 and ProEGF exhibited higher diagnostic capacity (AUC =
0.80 and p < 0.001; n = 163) than either marker alone (Table 4).
3.7. Correlations of SAA4 and ProEGF with clinical data
In this study, we used age-matched elder hernia patients as
normal controls. The average ages of control and cancer
subgroups were all more than 60 years old (Supplemental
Table 1). In this study, age-matched hernia patients were
chosen as the control subgroup because of no pathological
problems in their urological system. The possible changes of
urine proteome caused by age difference could be excluded.We
furthered subgrouped the smoking and non-smoking patients.
The detailed information of patient gender and smokers are
summarized in Supplemental Table 5A. Although the gender
wasnot completelymatchedbetweenhernia and cancer groups
due to the disease characteristics, the chi square test was
performed to confirm that the expression levels of SAA4 alone,
proEGF alone, and SAA4 and proEGF panel were not correlated
with age, gender, or smoking in both hernia and cancer patients
(all p-values were not smaller than 0.05, Supplemental Table
5A). Therefore, the changes of the discovered marker (panel)
should not be caused by the age, sex, or smoking.
Supplemental Table 5B showed that the discovered marker
panel was correlated statistically with tumor size (2 cm as
cutoff value) and tumor invasion status (p < 0.05), but not
correlatedwithmetastasis or distantmetastasis. A significantly
changes in levels of SAA4 (P = 0.009) and SAA4-ProEGF panel
(p < 0.001) were observed in T1–T4 tumors as comparedwith Ta
tumors. Taken together, our data suggest that the newly
discovered urinary marker panel might have the potential to
detect bladder cancer as well as to monitor the possibility of
progression after initial resection of different tumor size and
tumor grade of high-risk individual.
In clinical scenarios, these urinary tumor markers or marker
panel could be clinically applicable in three circumstances
(Supplemental Fig. 4). Firstly, in initial approach for any
suspicion of bladder urothelial carcinoma, the patient may be
much sure of this disease entity in the presence of gross
hematuria, especially when the patient is not ready or refuses
any invasive procedure in the beginning. Secondly, in thefollow-up phase after definite tumor resection is completed,
themarkers may provide as a surrogate for repeated cystoscopy
every 3 to 6 months for several years. An intriguing instance
may be for any patient who is high tumor grade or carcinoma in
situ that likely to be recurrent andhighprobability of progression
tomuscle invasion.High index of suspicion of recurrencemay be
warranted if these sensitive markers are positive but negative
image study and negative cystoscopy. Thirdly, for patient
with advanced stage after radical cystectomy, the only urinary
marker is urine cytology which is recognized as lack of
sensitivity. These convenient urinary markers may prompt
attention to prevent progression to incurablemetastatic disease.
3.8. Assessment of the diagnostic efficacy of SAA4 and
ProEGF in detecting kidney cancer
The renal and urological system produces urine and maintains
homeostasis. Urine is produced in the kidneys, and then is
collected and stored by the bladder before disposal through
urination. Bladder tumors account for 90–95% of urothelial
carcinomas, the most commonmalignancy of the urinary tract
[27]. Transitional cell carcinoma (TCC) accounts for about 90%of
bladder cancer [4]. Although the candidate biomarkers de-
scribed abovewere discovered in urine specimens from bladder
cancer patients, they may indicate the dysfunction of organs in
the urinary tract in addition to the bladder. Thus, these
candidate biomarkers should also be validated in urological
carcinomas other than bladder cancer to clarify their relevance
to individual urinary tract organs and tumor locations. Kidney
cancer ismore common inmen than inwomen (2:1) and occurs
in patients between the ages of 50 and 70 years, similar to
bladder cancer. There are several types of kidney cancer; the
two most common types are renal cell carcinoma (RCC) [28,29]
and urothelial cell carcinoma of the renal pelvis. RCC accounts
for more than 90% of kidney carcinomas [30]. Nearly all renal
pelvis cancers, which constitute less than 10% of kidney
carcinomas [30], are of the TCC type similar to the major type
of bladder cancer. Therefore, to further explore the clinical
utility of urinary SAA4 and proEGF, we measured their levels in
RCC and TCC subtypes of kidney cancer.
Table 5 summarizes the changes inurinary SAA4 andProEGF
levels in kidney cancer specimens and the diagnostic efficacy of
SAA4 and ProEGF in detecting kidney cancer. We found that
urinary SAA4 levelswere significantly elevated inTCC (70.6-fold
increase; p < 0.001 and AUC = 0.934) and RCC (8.0-fold increase;
p < 0.001 and AUC = 0.826) subgroups of kidney cancer com-
pared to hernia (Fig. 5B). Average levels of urinary ProEGF were
decreased by 70% in TCC-type kidney cancer, but showed no
significant difference between RCC-type kidney cancer and
hernia (Fig. 6B). Thus, this analysis revealed that the changes in
urinary SAA4 and ProEGF levels followed similar trends in both
bladder cancer and TCC-type kidney cancer subgroups (Tables 4
and 5). SAA4 levels were increased in urine specimens from
bladder cancer, TCC and RCC of kidney cancer with statistic
p-values, and urinary ProEGF levels was only decreased
significantly in bladder cancer, but not in kidney cancer. SAA4
can be used to differentiate bladder cancer from TCC-type
kidney cancer (p < 0.001 and AUC = 0.831; n = 116), whereas
ProEGF levels are capable of differentiating bladder cancer from
RCC-type kidney cancer (p < 0.001 and AUC = 0.824; n = 123).
Fig. 5 – Validation of SAA4 in 203 individual urine samples by Western blot analysis. The sample cohort contained 69 hernia
controls, 105 samples of bladder cancer (30 LgEs, 50 HsEs, and 25 HgAs subgroups), and 29 samples of kidney cancer (11 TCC
and 18 RCC subtypes). (A) Equal amounts of protein prepared from individual urine samples were separated by SDS-PAGE,
transferred to PVDF membranes, and probed with antibodies against SAA4. (B) Quantification of the results in A. The average
fold-difference between each subgroup and the hernia subgroup is labeled above each box plot. A pooled urine sample
prepared from six bladder cancer patients was used as an internal standard to normalize the intensity of each target protein
detected. The horizontal lines in each box plot denote the 10th, 25th, 50th, 75th, and 90th percentiles of the data distribution.
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differentiate hernia from bladder cancer, low-grade from
high-grade bladder cancer, hernia from all kidney cancers,
hernia from TCC-type kidney cancer, hernia from RCC-type
kidney cancer, RCC- from TCC-type kidney cancer, and bladder
cancer from RCC- and TCC-type kidney cancer (Table 5).
3.9. MetaCore analysis of biological networks associated
with urinary proteins dysregulated in bladder cancer
Finally, in order to interpret global changes in the urine
proteome associated with bladder cancer, we analyzed the361 proteins whose levels were significantly different bet-
ween hernia controls and bladder cancer patients using
MetaCore software. The analysis revealed that 17 pathways
were significantly associated with these dysregulated uri-
nary proteins (p < 0.001), including immune-response, blood-
coagulation, cell-adhesion, development, transport, and
cytoskeleton-remodeling pathways (Supplemental Table 6).
As shown in Supplemental Fig. 5A–B, the most significant
biological networks identified were the immune-response/
alternative complement pathway and blood-coagulation
pathway, with p-values of 1.66 × 10−21 and 6.99 × 10−20,
respectively.
Fig. 6 – Validation of proEGF in 192 individual urine samples by Western blot analysis. The sample cohort used and
experimental details were the same as those described in Fig. 5, except anti-proEGF antibody was applied to detect proEGF in
urine samples.
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Although there have been some studies for bladder cancer
biomarker discovery in urine, those potential markers discov-
ered, such as APOA1 [20,31], myoglobin, and fibrinogen [31],
belong to abundant protein category found in a variety of
human body fluids including serum/plasma. In this study, we
used accurate iTRAQ-based quantitative technology to evaluate
the reproducibility of two abundant protein–depletion ap-
proaches for urine biomarker discovery and identified proteins
that were differentially expressed in the urine proteome of
bladder cancer patients. With the incorporation of abundant
protein depletion in this work, more medium-minor abundantproteins could be quantified for the first time inurine proteome.
Therefore, the result of quantitative analysis of depleted urine
proteomeprovidednovel candidates for further investigation as
biomarkers for the non-invasive detection of bladder cancer. A
marker panel composed by two novel biomarker candidates,
SAA4 and proEGF, was first discovered and verified successfully
using Western blotting. To the best of our knowledge, the
associations of urinary SAA4 and proEGF with bladder tumor
and kidney cancer have not been mentioned before. In the
present study, we discovered and verified SAA4 and proEGF as
potential bladder cancer biomarker for the first time.
The specificity issue represents one of the major challenges
in bladder cancer biomarker discovery. This issue is complicated
by hematuria—the presence of blood-derived proteins in urine,
Table 4 – Summary of statistical analyses of the efficacy of APOA4, TIM, SAA4 and ProEGF urine levels in detecting bladder
and kidney cancers.
Protein name Hernia vs. all BC Hernia vs. LgEs Lg vs. Hg Es vs. As
p-value for
diagnosis
AUC p-value for early
detection
AUC p-value for grade
differentiation
AUC p-value for stage
differentiation
AUC
APOA4 0.400 0.538 0.796 0.484 0.483 0.544 0.781 0.519
(n = 174) (n = 99) (n = 105) (n = 105)
TIM 0.686 0.518 0.223 0.577 0.164 0.587 0.109 0.606
(n = 174) (n = 99) (n = 105) (n = 105)
SAA4 <0.001 0.684 0.508 0.542 <0.001 0.749 0.008 0.677
(n = 174) (n = 99) (n = 105) (n = 105)
ProEGF <0.001 0.705 0.003 0.691 0.910 0.493 0.863 0.511
(n = 163) a (n = 88) a (n = 105) a (n = 105) a
Panel (SAA4 + ProEGF) <0.001 0.796 0.033 0.639 <0.001 0.719 0.037 0.638
(n = 163) (n = 88) (n = 105) (n = 105)
Statistically significant values (p value ≤0.050 or AUC values >0.7) are highlighted in bold.
a Measured by Western blot analyses based on constant amount of total urine protein.
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The urine red blood cells (RBC) test, the most common way to
measure the presence of hematuria in urine.We have examined
the relationship between hematuria and the urinary levels of
SAA4, proEGF and combined panel, which showed a low
correlation (r = −0.196–0.453, n = 95–116, Supplemental Fig. 6).
Therefore, the alteration of urine levels of SAA4 and proEGF in
bladder cancer patients could not be predicted by the degree of
hematuria in urine.
4.1. Biological significance of SAA4 and ProEGF in disease
Members of the serum amyloid A (SAA) family of acute-phase
proteins are expressed at sites of inflammation [32]. SAA4exists
as a minor apolipoprotein on high-density lipoprotein in
plasma and is a minor acute-phase reactant in humans [33].
SAA4 can be used as a possible nutritional marker of hepatic
protein synthesis in the absence of inflammation [33]. To the
best of our knowledge, the alteration of SAA4 levels in body
fluids of diseased patients are limited. We found more than a
3-fold increase in urinary SAA4 levels in bladder cancer and
kidney cancer specimens. In addition, the degree towhichSAA4
levels were increased was related to the disease status of
bladder cancer patients, suggesting the potential use of urinary
SAA4 levels as a grade discriminator. Taken together, theseTable 5 – Summary of statistical analyses of the efficacy of SAA









p-value AUC p-value AUC p-value
SAA4 <0.001 0.867 <0.001 0.934 <0.001
(n = 98) (n = 80) (n = 87)
ProEGF 0.978 0.502 0.342 0.591 0.502
(N = 87)a (N = 69)a (N = 76)
Panel (SAA4 + ProEGF) <0.001 0.878 <0.001 0.966 <0.001
(n = 87) (n = 69) (n = 76)
Statistically significant values (p value ≤0.050 or AUC values >0.7) are hig
Measured by Western blot analyses based on constant amount of total ufindings indicate that urinary SAA4 is a novel biomarker for
detecting urological system tumors. Additional studies using a
larger set of clinical specimens will be required to confirm the
clinical utility of urinary SAA4.
We also found here for the first time that urinary proEGF
levels were significantly decreased in bladder cancer patients
(Fig. 6 and Table 4). Information regarding the association of
proEGF with human diseases is also very limited. Previously, the
cytoplasmic domain of the human proEGF transmembrane
region was reported as a novel suppressor of human thyroid
carcinoma cell motility and cathepsin L-mediated elastinolytic
invasion [34]. We observed that urinary proEGF levels were
decreased only when the tumor was located in transitional cells,
including bladder cancer and TCC-type kidney cancer subgroups.
Interestingly, urinary proEGF levels were not significantly altered
in RCC-type kidney cancer patients with tumors located in renal
cells. Therefore, proEGF might be a useful clinical indicator of
tumor location in urological carcinomas. Verification of this will
also require additional, larger-scale studies.
4.2. Pathway analysis of the bladder cancer urine proteome
Using MetaCore software to interpret global changes in the
urine proteome caused by bladder cancer, we identified












AUC p-value AUC p-value AUC p-value AUC
0.826 0.005 0.818 <0.001 0.831 0.497 0.550
(n = 29) (n = 116) (n = 123)
0.447 0.088 0.692 0.085 0.658 <0.001 0.824
a (N = 29) (N = 116) (N = 123)
0.831 <0.001 0.934 0.001 0.799 <0.001 0.832
(n = 29) (n = 116) (n = 123)
hlighted in bold.
rine protein.
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coagulation pathways (Supplemental Fig. 5A–B). Of the 39
network objects (i.e., the molecules that comprise the net-
work) for the two pathways, 19 and 18 were quantified as
differential proteins in immune response and blood-
coagulation pathways, respectively. Studies have shown that
the complement system is a major effector of the humoral
branch of the immune system, acting to protect the host from
microorganisms [35]. In the operation of this system, larger
fragments resulting from cleavage of a component bind to
targets near activation sites, whereas smaller fragments diffuse
from the site andmay initiate localized inflammatory responses
by binding to specific receptors. Complement fragments interact
with each another to form functional complexes. Multiple
complement components interact sequentially to form a mac-
romolecular structure called membrane attack complex. This
complex creates pores in the cell membrane and induces cell
lysis [36–38]. The hemostatic system maintains the fluidity of
blood under normal conditions and responds to vessel injury
by rapidly forming a clot consisting of platelets and fibrin.
Thrombin generated during propagation of both cascades
converts fibrinogen to a fibrin network. Thrombin also activates
coagulation factor XIII, which is a transglutaminase that
stabilizes the clot through covalent cross-linking of fibrin [39].
The fibrin clot is ultimately resorbedduring fibrinolysis. Plasmin,
generated from plasminogen, is the major fibrinolytic protease.
Conversion of plasminogen to plasmin could be triggered
by both tissue plasminogen activator and the plasminogen
activator, urokinase (PLAU). Under certain conditions, plasma
kallikrein is also capable of stimulating plasmin generation [40].
Both blood coagulation and fibrinolysis are under the fine
control of various regulators. Our iTRAQ study indicates that
blood-coagulation and immune-response pathways are likely
simulated during bladder tumor development and invasion. The
proteins involved in these pathways are probably secreted into
urine, a proximal fluid for the bladder. Therefore, most of the
identified proteins associated with the two pathways showed
increased levels in the bladder cancer urine proteome.
Another interesting pathway that was significantly
altered (p = 2.49 × 10−4) is the cell adhesion–PLAU signaling
pathway (Supplemental Fig. 5C). The binding of PLAU to its
glycosylphosphatidylinositol-anchored PLAU receptor (PLAUR)
mediates a variety of functions, including inflammation, vascu-
lar homeostasis, and tissue repair [41]. PLAU plays an important
role in the regulation of migration and cell adhesion during
tissue remodeling, and activates intracellular signaling upon
binding to certain receptors on the cell surface [42–44]. In our
iTRAQ data, urinary levels of PLAUwere decreased in all bladder
cancer subgroups. Several previous investigations have reported
an association between PLAU and bladder cancer [45–47]. These
studies showed that PLAU levels in cancer tissues are signifi-
cantly lower in low-grade and non-invasive cancers than in
advanced cancers, suggesting PLAU as a useful prognostic
marker of recurrence and progression of superficial bladder
cancer [45,46]. Lin and co-workers identified PLAU protein in the
culture media of bladder cancer cell lines and reported that
pro-PLAUwas present at low levels or was absent in the urine of
patients with high-grade, advanced-stage bladder tumors [47].
They speculated that pro-PLAU may be more readily converted
to PLAU in cancer cells, resulting in the subsequent loss ofpro-PLAU in the urine of cancer patients [47]. This inference is
consistent with the notion that tissue and body fluid proteomes
may not always be congruent due to biological transformations.
The clinical significance of PLAU in relation to bladder tumors
warrants further study.5. Conclusions
In this study, we evaluated the reproducibility and applicability
of two different approaches for abundant-protein-depletion in
human urine. An immuno-based MARS Hu-14 depletion
column was selected for coupling with isobaric labeling and
multiple-dimensional LC to discover bladder cancer biomarkers
using a retrospective cohort of urine samples. Six apolipopro-
teins and four additional proteins (APOA4, TIM, SAA4, and
ProEGF) were verified using Bio-plex assays or Western blot
analyses. All six apolipoproteins were able to differentiate
bladder cancer from hernia with statistical significance. Addi-
tionally, the combination of SAA4 and proEGF exhibited higher
diagnostic capacity (AUC = 0.80 and p < 0.001) than either
marker alone. A MetaCore analysis of biological networks
revealed that immune-response/alternative complement and
blood-coagulation pathways were most notably altered in the
urine proteome of bladder cancer patients. This study confirmed
the clinical significance of alterations in the urine proteomewith
respect to urological tumors and identified several urinary
biomarkers for detecting bladder cancer. Further experiments
will be required to validate clinical utility using independent sets
of clinical samples and a prospective study design.
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